A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Phase 1 Completed 37 enrolled GlaxoSmithKline

Non-randomizedParallel-groupOpen-labelPrevention

Summary

GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study is designed to test the safety and the extent of the GW679769 affect on dexamethasone and ondansetron levels in humans.

Timeline

Start: 2007-02-19
Primary completion: 2007-05-15
Completion: 2007-05-15

Publications

Background Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer. 2009 Sep;17(9):1177-85. doi: 10.1007/s00520-008-0571-5. Epub 2009 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Casopitant	Small molecule	50 mg	Oral
Subject	Dexamethasone	Small molecule	8 mg	Oral
Subject	Ondansetron	Other / unclassified	8 mg	Oral
Subject	Ondansetron	Other / unclassified	32 mg	Oral

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Summary

Timeline

Publications

Drugs

Indications